Highlight
– This large German multicenter registry study compared first-line carboplatin/paclitaxel (CP) chemotherapy with other cytotoxic regimens in anaplastic thyroid cancer (ATC).
– No significant differences in progression-free or overall survival were observed between CP and other chemotherapy approaches.
– Age, lymph node, and distant metastasis were key prognostic factors; surgery conferred a survival benefit.
– Rapid molecular diagnostics remain essential for personalized approaches, as chemotherapy mainly serves as a bridging strategy to alternative treatments.
